Abstract:Porcine circovirus type 2 (PCV2) is one of the most serious pathogens in pig herds worldwide. The Capsid protein (Cap), a structural protein of PCV2, is involved in the host's immune response; it induces neutralizing-antibody production and has good immunogenicity. The main PCV2 subtype currently prevalent in the Chinese pig herd is PCV2d. In this study, We constructed a recombinant Bacillus subtilis (B. subtilis) capable of secreting Cap protein, named pHT43-Cap/B. subtilis; we concentrated the supernatant of the recombinant bacteria and observed virus-like particles (VLPs) of PCV2d formed by Cap protein under transmission electron microscopy, named PCV2d-VLPs. The immunocompetence of the pHT43-Cap/B. subtilis and PCV2d-VLPs were then assessed by oral administration and by intramuscular injection into mice, respectively. The results showed that the levels of PCV2d-Cap protein-specific IgG in the serum and of PCV2d-Cap protein-specific sIgA in the small intestinal fluid of pHT43-Cap/B. subtilis immunized mice were elevated compared to the control group, both of them highly significant (p < 0.01), and the corresponding serum-specific IgG antibodies were effective in neutralizing PCV2d virulence. The virus load in the liver of the immunized mice was significantly lower than that in the control group (p < 0.01), as was the virus load in the spleen and lungs of the immunized mice (p < 0.05). In addition, the serum levels of PCV2d-Cap-specific IgG in mice immunized with PCV2d-VLPs by intramuscular injection were significantly elevated compared to the control group (p < 0.05), and the viral load in all tissues was significantly lower in immunized mice (p < 0.05). In conclusion, the recombinant bacterium pHT43-Cap/B. subtilis can induce effective mucosal and humoral immunity in mice, PCV2d-VLPs can induce humoral immunity in mice, and both vaccines have good immunogenicity; these results provide a theoretical and material basis for the development of a new vaccine against PCV2d.

Recombinant virus-like particles obtained with PPV VP2 and PCV2 ORF2 and their immunogenicity

Obtaining of Union Expression Virus-Like Particle of PPV VP2 and PCV2 ORF2 and Its Immunogenicity

Development Of Recombinant Porcine Parvovirus-Like Particles As An Antigen Carrier Formed By The Hybrid Vp2 Protein Carrying Immunoreactive Epitope Of Porcine Circovirus Type 2

Construction of the Eukaryotic Expression Plasmid with PPV VP2 Gene and PCV2 ORF2 Antigen Predominance Region Gene and Study on Immunogenicity of the Plasmid

Porcine Parvovirus Capsid Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles with High Immunogenicity in Mice and Guinea Pigs.

Construction and immunogenicity of nucleic acid vaccine of porcine parvovirus VP2 gene

Co-expression of Porcine INF-γ Gene and Its Molecular Adjuvant Effects on the PPV VP2-PCV2 ORF2 Eukaryotic Plasmid

Construction of Porcine parvovirus VP_2 Nucleic Acid Vaccine and Analysis of Its Immunogenicity in Mice

Study on Gene Immunity of Porcine Parvovirus Structural Protein Genes VP1 and VP2

Development of expressing porcine parvovirus-like particles formed by the VP2 protein in recombinant pseudorabies virus

A novel recombinant pseudorabies virus expressing parvovirus VP2 gene: Immunogenicity and protective efficacy in swine

Construction and Immunogenicity of Eukaryotic Plasmid Expressing B Lymphocyte Epitope Gene of ORF2 of Porcine Circovirus Type 2 Fused with VP2 Gene of Porcine Parvovirus

Expression of Porcine parvovirus-like Particles Carrying a CSFV T Cell Epitope and Its Immunization on Mice

Construction and immune efficacy of eukaryotic expression vectors of PPV VP2 gene with different antigen epitopes of PCV2 ORF2 gene

Both recombinant Bacillus subtilis Expressing PCV2d Cap protein and PCV2d-VLPs can stimulate strong protective immune responses in mice

Immunogenicity of a Recombinant Pseudorabies Virus Expressing ORF1–ORF2 Fusion Protein of Porcine Circovirus Type 2

The Effect of Co-expression of PPV VP2 and PCV2 ORF2 on PPV Virus-like Particles' Formation

Development of a Novel PCV2 and PCV3 Vaccine Using Virus-Like Vesicles Incorporating Venezuelan Equine Encephalomyelitis Virus-Containing Vesicular Stomatitis Virus Glycoprotein

Large-scale manufacture of VP2 VLP vaccine against porcine parvovirus in Escherichia coli with high-density fermentation

Immunogenicity and Immunoprotection of PCV2 Virus-like Particles Incorporating Dominant T and B Cell Antigenic Epitopes Paired with CD154 Molecules in Piglets and Mice

[Effect of the Glycine-Rich Region Deleted PPV VP2 to the VLPs].